title: Reversibility from delayed hyperacute rejection in ABO-incompatible renal transplantation: histopathological findings of renal allograft biopsy.
abstract: ABO-incompatible renal transplantation (ABOIRTx) tend to lead to blood type antibody-mediated rejection, the so-called delayed hyperacute rejection (DHAR), which results in short-term graft loss. To clarify the accurate incidence and prognostic value of DHAR among ABOIRTx, we reviewed biopsy specimens obtained from ABOKTx allografts with abrupt dysfunction during the early period after transplantation. Among 74 ABOIRTx patients, 34 patients displayed allograft dysfunction within 14 days following transplantation. The biopsy specimens were classified based on the Banff schema. The pathological diagnosis of ABO blood type antibody-mediated humoral rejection (ABO-AMHR) was made by the following 3 findings: Specimens with all of above-mentioned findings were categorized as severe ABO-AMHR; those with at least one findings, were categorized as mild ABO-AMHR. All patients were treated with steroid pulse therapy and/or modification of other immunosuppressants. Group 1 consisted of severe ABO-AMHR (n = 6); group 2 consisted of mild ABO-AMHR (n = 5); group 3 consisted of acute cellular rejection (n = 3); group 4 consisted of recovery phase of ATN (n = 11); group 5 consisted of calcineurin inhibitor toxicity (n = 2); and group 6 consisted of normal histology (n = 5). One of 6 patients (16%) in group 1 lost the graft because of DHAR irreversible by antirejection and anticoagulation therapy. However, there has been no clear definition of histpathological criteria for DHAR after ABO-incompatible kidney transplantation. The definition must prognosticate whether the rejection process is reversible.
authors.affiliation: Department of Nephrology, Toho University Omori Hospital, Tokyo, Japan. ken-1108-s@mua.biglobe.ne.jp
authors.forename: K
authors.initials: K
authors.lastname: Sugiyama
authors.forename: K
authors.initials: K
authors.lastname: Arai
authors.forename: A
authors.initials: A
authors.lastname: Aikawa
authors.forename: M
authors.initials: M
authors.lastname: Miyagi
authors.forename: T
authors.initials: T
authors.lastname: Ohara
authors.forename: A
authors.initials: A
authors.lastname: Hasegawa
authors.forename: M
authors.initials: M
authors.lastname: Muramatsu
authors.forename: N
authors.initials: N
authors.lastname: Hirayama
authors.forename: E
authors.initials: E
authors.lastname: Tajima
authors.forename: T
authors.initials: T
authors.lastname: Kawamura
authors.forename: H
authors.initials: H
authors.lastname: Ogihara
authors.forename: T
authors.initials: T
authors.lastname: Hadano
authors.forename: H
authors.initials: H
authors.lastname: Nakano
mesh_terms: D000017:ABO Blood-Group System; D000328:Adult; D001706:Biopsy; D001787:Blood Group Incompatibility; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000276:immunology*; D006801:Humans; D015994:Incidence; D007518:Isoantibodies / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology*; D008297:Male; D011183:Postoperative Complications / Q000097:blood / Q000276:immunology; D012189:Retrospective Studies; D013156:Splenectomy; D014184:Transplantation, Homologous / Q000276:immunology / Q000473:pathology
chemical_list: D000017:ABO Blood-Group System; D007518:Isoantibodies